MOBIX LABS, INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MOBIX LABS, INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | $6.44M | Dec 26, 2024 |
| FY2024 | Sep 30, 2023 | $1.22M | Dec 26, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $9.91M | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $6.44M | Jan 13, 2026 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $5.01M | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $2.55M | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | ($396.0K) | Dec 26, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($46.13M) | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | ($20.03M) | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | ($39.62M) | Dec 26, 2024 |
| FY2022 | Dec 31, 2022 | ($776.1K) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $361.1K | Mar 31, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($37.69M) | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | ($46.40M) | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | ($35.54M) | Dec 26, 2024 |
| FY2022 | Dec 31, 2022 | ($1.26M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($762.5K) | Mar 31, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.42M | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $5.78M | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | $11.04M | Dec 26, 2024 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $39.56M | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $41.84M | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | $24.10M | Dec 26, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($10.11M) | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | ($18.39M) | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | ($14.63M) | Dec 26, 2024 |
| FY2022 | Dec 31, 2022 | ($321.0K) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($1.13M) | Mar 31, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $26.0K | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $44.0K | Jan 13, 2026 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $37.11M | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $39.09M | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | $18.75M | Dec 26, 2024 |
| FY2022 | Dec 31, 2022 | $10.01M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $80.68M | Mar 31, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $37.45M | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $33.56M | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | $21.79M | Dec 26, 2024 |
| FY2022 | Dec 31, 2022 | $2.42M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $1.74M | Mar 31, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($336.0K) | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $5.53M | Jan 13, 2026 |
| FY2025 | Sep 30, 2023 | ($5.34M) | Jan 13, 2026 |
| FY2022 | Dec 31, 2022 | ($2.15M) | Mar 31, 2023 |
| FY2024 | Sep 30, 2022 | ($9.42M) | Dec 26, 2024 |
| FY2022 | Dec 31, 2021 | ($1.06M) | Mar 31, 2023 |
| FY2022 | Mar 18, 2021 | $0 | Mar 31, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $16.07M | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $16.07M | Jan 13, 2026 |
| FY2025 | Sep 30, 2023 | $5.22M | Jan 13, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($150.59M) | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | ($104.46M) | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | ($83.76M) | Dec 26, 2024 |
| FY2022 | Dec 31, 2022 | ($2.15M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($1.06M) | Mar 31, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $175.8K | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | $240.7K | Mar 31, 2023 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $6.19M | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $3.42M | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | $6.59M | Dec 26, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (1) | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | (2) | Dec 26, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (1) | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | (2) | Dec 26, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 2.00M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | 2.00M | Mar 31, 2023 |